What Is This?
For most of the 20th century, psychedelics were simultaneously the most politically toxic and the most scientifically promising drugs in medicine. The first wave of research, from 1950 to 1970, produced over 1,000 clinical papers on LSD and psilocybin for addiction, anxiety, and depression — much of it credibly positive. Then the Controlled Substances Act of 1970 classified them Schedule I (no accepted medical use, high abuse potential), and clinical research effectively stopped for three decades.
The second wave began at Johns Hopkins and NYU in the 2000s, working through an extraordinary regulatory environment to restart trials. What they found confirmed the earlier research and added something the first wave lacked: a mechanistic explanation for why these substances produce lasting therapeutic effects.
The answer is neuroplasticity — the brain's capacity to form new connections, reorganise its structure, and change its patterns of processing. Psychedelics appear to open a temporary window of enhanced neuroplasticity — a period in which the brain becomes unusually receptive to new learning, new patterns, and the formation of new associations. The mystical experience is not the mechanism. The plasticity window is. And in that window, therapeutic content — the insights gained, the memories processed, the behaviours practised — has a disproportionate chance of becoming permanent.^1
The field has now matured to the point of FDA Phase 3 trials, regulatory approvals, and clinical deployments at scale. Ketamine is already FDA-approved and available in hundreds of clinics. Psilocybin has received FDA Breakthrough Therapy designation and is in Phase 3 trials. MDMA was rejected by the FDA in August 2024 (on methodological grounds, not safety or efficacy) and is continuing through additional trials. Australia legalised supervised psilocybin therapy in 2023. Oregon (2023) and Colorado (2024) have followed in the US.
Why Does It Matter?
- The efficacy data for treatment-resistant conditions is unlike anything in psychiatry. Standard antidepressants work for roughly 50% of first-line patients and require months of daily dosing. Treatment-resistant depression (TRD) responds to SSRIs in perhaps 10-20% of cases. COMPASS Pathways' Phase 2b psilocybin trial: after just two doses, depression severity dropped from 22.8 to 8.7 (a 62% reduction) at one week, with 75% of patients maintaining response and 58% in remission at 12 months. This is not a mild effect. For MDMA-assisted PTSD therapy, Phase 3 trials showed 67% response rate vs 32% placebo — also extraordinary by psychiatric standards.^2
- It works differently from everything else in psychiatry. SSRIs require daily dosing indefinitely; they manage symptoms but don't change underlying patterns. Psychedelic-assisted therapy produces lasting changes from a small number of supervised sessions (typically 1-3). The neuroplasticity model explains why: during the plasticity window, therapeutic work produces structural changes in the brain that persist after the drug clears. You're not managing chemistry continuously; you're changing structure discontinuously.
- The mechanism is now understood well enough to be specific. Psilocybin (via its active metabolite psilocin) binds to 5-HT2A serotonin receptors, which are densely expressed in the default mode network (DMN) — the brain's self-referential processing system. Overactivity of the DMN is strongly associated with depression and rumination. Psilocybin suppresses DMN activity, disrupts entrenched self-referential loops, and simultaneously increases BDNF (brain-derived neurotrophic factor) — the protein most responsible for synaptic growth and neuroplasticity. Ketamine works differently: NMDA receptor blockade produces rapid synaptogenesis (new synaptic connections) within hours, which is why it produces antidepressant effects in hours rather than weeks. MDMA releases a cocktail of serotonin, dopamine, norepinephrine and oxytocin, reducing amygdala fear reactivity and enabling fear extinction — the therapeutic mechanism for PTSD.^3
- It's shifting psychiatry's fundamental model. The serotonin hypothesis of depression (famously debunked in the 2022 Moncrieff review) positioned psychiatric drugs as chemistry managers. The neuroplasticity model positions them as change enablers. This is a different category of intervention: instead of suppressing symptoms, you create conditions for structural change and let therapy fill the plasticity window with new patterns. The therapeutic relationship becomes more important, not less, as the drug's role is contextualised as creating opportunity rather than providing treatment.
- The regulatory and legal landscape has shifted more in five years than in the previous 50. Australia legalised supervised psilocybin and MDMA-assisted therapy in 2023. Oregon launched the first legal supervised psilocybin services in the US in 2023. Colorado followed in 2024. Ketamine is legally and widely available now. The policy dam is breaking, driven by clinical evidence that legislators can no longer ignore.
Key People & Players
Robin Carhart-Harris (UCSF) — The most influential active researcher in psychedelic neuroscience. His REBUS model ("Relaxed Beliefs Under Psychedelics") proposes that psychedelics reduce the brain's tendency to impose prior expectations on experience, producing a period of more bottom-up, sensory-driven processing. His fMRI work mapped what the brain actually does under psilocybin, making the neuroplasticity mechanism visible.^4
Matthew Johnson (Johns Hopkins) — Runs the Johns Hopkins Centre for Psychedelic and Consciousness Research, the most prominent clinical research programme. His work on psilocybin for smoking cessation (80% abstinence rate at 6 months, compared to ~35% for best current treatments) is among the most striking results in the field.
David Nutt (Imperial College London) — Neuropsychopharmacologist and former chair of the UK's Advisory Council on the Misuse of Drugs (from which he was famously fired for publishing that ecstasy was statistically safer than horse riding). Has run multiple psychedelic neuroimaging studies and is the most outspoken advocate for evidence-based drug policy reform.
MAPS (Multidisciplinary Association for Psychedelic Studies) — The non-profit that funded and ran the Phase 3 MDMA-PTSD trials, through the LYKOS Therapeutics spinout. The FDA rejection in August 2024 was a setback, but MAPS's 30-year investment in the research infrastructure made the current moment possible.
Michael Pollan — Author of How to Change Your Mind (2018), the book that shifted psychedelics from subcultural interest to mainstream conversation. Not a researcher, but the most effective science communicator in the field. His Netflix documentary of the same name extended the reach further.
Andrew Huberman — Has done more than anyone in the podcast/wellness space to explain the neuroplasticity mechanism clearly and distinguish the evidence-based from the speculative. His episodes on neuroplasticity and psychedelics have reached audiences that traditional scientific communication hasn't.
The Current State
The regulatory picture is complex and moving fast. Here's the current state (as of early 2026):
Ketamine/Esketamine (Spravato): Fully FDA-approved since 2019 for treatment-resistant depression. Available in ~700 infusion clinics in the US. The most immediately accessible psychedelic-adjacent treatment. Rapid onset (hours). Works differently from other antidepressants (NMDA antagonism rather than serotonin). Some debate about durability of effect (some patients require repeated infusions).^5
Psilocybin: FDA Breakthrough Therapy designation. 7 Phase 3 trials (5 for psilocybin, 2 for esketamine). Oregon and Colorado have state-legal supervised services operating now. Australia legalised clinical use in 2023. FDA approval as a prescription drug — if trials continue positively — could come within 2-5 years.^6
MDMA: FDA rejected the LYKOS NDA in August 2024, citing concerns about trial blinding (hard to blind a drug that produces obvious subjective effects) and the independence of evaluators. The efficacy data was strong. Additional trials are proceeding with improved methodology. Reapplication likely 2026-2027. Australia included MDMA in its 2023 legalisation.
LSD and DMT: Phase 2 trials for anxiety (LSD) and depression (DMT). Further behind psilocybin and MDMA.
The neuroplasticity window — key practical insight:
The emerging understanding is that the therapeutic effect depends on what happens during the neuroplasticity window, not just on taking the drug. This has two implications. First: set and setting are not peripheral — they're central to the mechanism. A plasticity window opened in a supportive, therapeutically structured context produces different outcomes than the same window opened in a chaotic or frightening environment. Second: therapeutic preparation (before the session) and integration (processing experiences after the session) are where most of the clinical benefit is produced. The drug is the key that opens the lock; therapy is what happens after the door is open.
The self-experimentation landscape:
Outside clinical settings, significant communities self-administer psychedelics for mental health and personal development. Psilocybin mushrooms are decriminalised in multiple US cities. The risks of unsupervised use are real — adverse experiences, HPPD (hallucinogen-persisting perception disorder, rare but real), psychological destabilisation in vulnerable individuals, contraindications with SSRIs (serotonin syndrome risk with some combinations). But the risk profile in healthy adults under appropriate conditions is substantially lower than Schedule I classification implies, and the harm reduction information available has improved dramatically.
Best Resources to Learn More
- How to Change Your Mind by Michael Pollan — The essential popular account. Covers history, neuroscience, and Pollan's own carefully managed experiences. The Netflix documentary covers similar ground in 4 hours.^7
- BMJ: Psychedelic Medicine — Mechanisms, Evidence, and Translation to Practice (2025) — The most current rigorous clinical review. Technical but accessible introduction and discussion.^8
- Johns Hopkins Centre for Psychedelic Research — The primary clinical research programme. Published papers, trial protocols, and public educational resources.^9
- Robin Carhart-Harris's REBUS model (Nature Reviews Neuroscience, 2019) — The foundational mechanistic paper. Dense but the abstract and figures explain the REBUS framework clearly.^10
- Huberman Lab: The Science of Psychedelics for Mental Health — 3+ hours, the best accessible deep-dive on mechanisms and clinical evidence.^11